The combination works by decreasing hunger and increasing the feeling of fullness. The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema ...

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release. The headline results from ...

Amitabh Bachchan’s character to play a more significant role in the sequel. The megastar will return to the sets in May to ...

Space Marine 2 launched back in 2023, it felt like everyone and their mum were bisecting Tyranids in the Emperor's name.

Canada’s move to align with the EU’s defence initiative marks a significant recalibration of its military strategy amid ...

In fintech, where every line of code has the potential to impact the financial ecosystem, one professional stands out for her ...

MFA has the potential to revolutionize cyberdefense in the 21st century. There is value to be gained from delving into its ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

Novo Nordisk’s phase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint. CagriSema is a fixed-dose combination of a long-acting ...

NVO's Novel Obesity Treatment Disappoints in Phase III Study Novo Nordisk's phase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint.